1. Home
  2. Directory
  3. Oklahoma
  4. Vinita
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1376523639

JAMES K BUTNER O.D.
Prescription History 1376523639
Optometrist in Vinita, OK


Quality Rating: 75 out of 100 score

NPI Status: Active since January 20, 2006

Contact Information

529 N WILSON ST
VINITA, OK
ZIP 74301
Phone: (918) 256-5543
Fax: (918) 256-6118

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JAMES K BUTNER O.D., an active Optometrist specialist practicing in Vinita, OK. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 891 documented patient claims. Among these therapy options, the most frequently utilized medication is Restasis, which accounts for 499 claims alone.

Medication Index

F
L
P
R
T
X
No matching medications currently found on file.

Fluorometholone

Generic Formulation: FluorometholoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 23
30-Day Fills 27.7
Days Supply 720
OK State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills49.8
Peer Average Days Supply1,366
Conservative Utilization

This provider writes prescriptions for this formulation 32.4% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,587.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.03

State Avg Cost Per Claim

$88.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Fluorometholone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 55
30-Day Fills 97.6
Days Supply 2,785
OK State Average Benchmarks
Peer Average Claims100.0
Peer Average 30-Day Fills170.5
Peer Average Days Supply4,871
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,055.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.36

State Avg Cost Per Claim

$23.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 206
30-Day Fills 377.0
Days Supply 10,930
OK State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills67.0
Peer Average Days Supply1,920
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 415.0% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103,721.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$503.50

State Avg Cost Per Claim

$445.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Prolensa

Generic Formulation: Bromfenac SodiumSpecialty: Optometry
Provider Metrics Summary
Total Claims 24
30-Day Fills 29.5
Days Supply 833
OK State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills61.2
Peer Average Days Supply1,674
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.0% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,843.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$660.13

State Avg Cost Per Claim

$349.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat swelling (inflammation) and pain in the eye after a certain type of eye surgery (cataract surgery). Bromfenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking the effects of certain natural substances (prostaglandins) that cause pain and inflammation.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 499
30-Day Fills 769.3
Days Supply 23,065
OK State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,589
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,412.1% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $506,763.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,015.56

State Avg Cost Per Claim

$1,039.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 48
30-Day Fills 130.2
Days Supply 3,902
OK State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills104.0
Peer Average Days Supply3,056
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $531.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.07

State Avg Cost Per Claim

$21.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 36
30-Day Fills 44.0
Days Supply 1,320
OK State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply829
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 89.5% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,834.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$884.29

State Avg Cost Per Claim

$946.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JAMES K BUTNER O.D. provides transparency into local medical care patterns within Vinita, OK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.